期刊
SCIENCE ADVANCES
卷 8, 期 19, 页码 -出版社
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/sciadv.abn1229
关键词
-
资金
- Deutsche Forschungsgemeinschaft
- National Cancer Institute [U01CA220323-A1, U24CA213274]
- Cancer Prevention and Research Institute of Texas (CPRIT) [RR20007]
- NIH [1K08CA237832]
- Lung Cancer Research Foundation [R01CA247232]
- Norwegian Cancer Society [182694]
- CCR startup funds
This study used patient-derived xenograft models to investigate acquired resistance to olaparib plus temozolomide in small cell lung cancer. The study revealed alterations in cell cycle kinetics and DNA replication, and demonstrated the potential of the serial model approach to investigate and overcome therapy resistance in SCLC. Notably, the study also identified a mechanism of acquired resistance involving up-regulation of translesion DNA synthesis.
In small cell lung cancer (SCLC), acquired resistance to DNA-damaging therapy is challenging to study because rebiopsy is rarely performed. We used patient-derived xenograft models, established before therapy and after progression, to dissect acquired resistance to olaparib plus temozolomide (OT), a promising experimental therapy for relapsed SCLC. These pairs of serial models reveal alterations in both cell cycle kinetics and DNA replication and demonstrate both inter- and intratumoral heterogeneity in mechanisms of resistance. In one model pair, up-regulation of translesion DNA synthesis (TLS) enabled tolerance of OT-induced damage during DNA replication. TLS inhibitors restored sensitivity to OT both in vitro and in vivo, and similar synergistic effects were seen in additional SCLC cell lines. This represents the first described mechanism of acquired resistance to DNA damage in a patient with SCLC and highlights the potential of the serial model approach to investigate and overcome resistance to therapy in SCLC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据